Unraveling the care pathway for CAR T-cell therapy in large B-cell lymphoma: insights from a nationwide study in France (2018-2023).

Fiche publication

Date publication

avril 2026

Journal

Leukemia & lymphoma

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis

Tous les auteurs :
Thieblemont C, Caillot D, Pierre M, Branchoux S, Lemasson H, Caron A, Nevoret C, Torreton E, Petel A, Despas F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42052989

Résumé

This study describes the inpatient care pathway for 1914 Large B-cell Lymphoma (LBCL) patients treated with CAR T-cell therapy in France between 2018 and 2023 and identifies factors influencing their management. Based on a retrospective analysis of the French national hospital database, we found the average CAR T-cell infusion stay was shorter for patients in the second line of treatment later lines (20.4 23.8 days). The specific product used was also influential; for example, lisocabtagene maraleucel was associated with shorter stays and fewer ICU admissions than axicabtagene ciloleucel. A multivariate analysis confirmed that while patient characteristics and the CAR T-cell product influenced outcomes, higher center experience was a primary determinant. More experienced centers had shorter hospital stays and a higher probability of patients being discharged home, demonstrating that the management of CAR T-cell patients is largely dependent on institutional experience.